Squarepoint Ops LLC Next Cure, Inc. Transaction History

Squarepoint Ops LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.38 - $5.27 $68,499 - $106,801	-20,266 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.76 - $6.24 $25,142 - $32,959	-5,282 Reduced 20.67%	20,266 $98,000
Q4 2021 Feb 14, 2022	SELL	$5.7 - $9.1 $37,779 - $60,314	-6,628 Reduced 20.6%	25,548 $153,000
Q3 2021 Nov 15, 2021	SELL	$6.74 - $8.02 $95,667 - $113,835	-14,194 Reduced 30.61%	32,176 $217,000
Q2 2021 Aug 16, 2021	BUY	$7.6 - $10.28 $223,234 - $301,954	29,373 Added 172.81%	46,370 $372,000
Q1 2021 May 17, 2021	SELL	$9.81 - $13.88 $78,244 - $110,706	-7,976 Reduced 31.94%	16,997 $170,000
Q4 2020 Feb 16, 2021	BUY	$9.47 - $12.43 $236,494 - $310,414	24,973 New	24,973 $272,000
Q2 2020 Aug 14, 2020	SELL	$21.19 - $40.2 $279,941 - $531,082	-13,211 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$32.32 - $58.37 $36,004 - $65,024	-1,114 Reduced 7.78%	13,211 $490,000
Q4 2019 Feb 14, 2020	SELL	$25.0 - $92.22 $251,875 - $929,116	-10,075 Reduced 41.29%	14,325 $807,000
Q3 2019 Nov 14, 2019	BUY	$15.73 - $41.6 $383,812 - $1.02 Million	24,400 New	24,400 $753,000

15.9M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $36.4M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.